Deerfield Management

# Signal Note: Deerfield Initiates $1.7B Position in Nuvalent Deerfield's sizable new stake in NUVL signals confidence in the company's pipeline of ALK and ROS1 inhibitors for non-small cell lung cancer, where it is advancing multiple clinical-stage programs targeting resistant mutations and brain metastases. The timing suggests conviction ahead of near-term data readouts, likely including updates on its lead ALK program; Deerfield's multi-strategy approach typically indicates belief in both clinical success probability and valuation upside. This represents a meaningful validation from a sophisticated healthcare investor but carries execution risk dependent on trial outcomes.

**Signal Note: Deerfield Initiates $321M Position in Cogent Biosciences** Deerfield's substantial entry into COGT likely reflects conviction in fabhalta (avapritinib) expansion beyond indications already approved or near-approval; the company is advancing the KIT/PDGFRA inhibitor in systemic mastocytosis and other mast cell disorders with multiple shots on goal through 2024-2025. This positions Deerfield to benefit from label expansion catalysts and potential commercial inflection if recent approvals (SM indication) drive revenue acceleration and de-risk the near-term cash runway.

# Signal Note: Deerfield Initiates $266M Position in PRAX Deerfield's $266M entry into Praxis signals confidence in the company's pipeline, likely driven by upcoming clinical catalysts in psychiatric disorders where Praxis is advancing TAAR1 agonists and other precision psychiatry assets. The timing suggests positioning ahead of near-term data readouts or regulatory milestones that could derisk the platform and validate the precision medicine thesis in CNS indications with high unmet need.

**Signal Note: Deerfield initiates $252M position in IONS** Deerfield's sizable entry into Ionis suggests conviction in the company's antisense pipeline, likely driven by near-term catalysts including potential FDA decisions on lead programs (spinraza generics risk, but newer candidates like AKCEA-APOC3 in cardiovascular disease and IONIS-FB-LRx in Factor B-mediated diseases offer growth vectors). The timing aligns with Ionis's shift toward partnered development and royalty-based revenue model, which may appeal to Deerfield's multi-strategy thesis on capital efficiency and reduced execution risk.

# Signal Note: Deerfield Management Initiates $251.6M Position in Viatris (VTRS) Deerfield's entry into VTRS—a $251.6M stake representing ~1.4% of shares outstanding—signals conviction in the generics/complex branded portfolio despite near-term headwinds from GLP-1 competitive pressure on older diabetes agents. The timing aligns with VTRS's cost reduction initiatives and potential M&A optionality, though the position lacks obvious near-term clinical catalysts given the company's focus on established brands (Mylan heritage) and generic manufacturing rather than pipeline advancement. Monitor for any strategic partnership announcements or dividend policy changes that could justify a multi-strategy investor's thesis.

# Signal Note: Deerfield Initiates $230M Position in Revolution Medicines Deerfield's $230M entry into RVMD signals confidence in the company's RAS(ON) program, particularly RMC-6236 in KRAS-mutant cancers where clinical data readouts are expected in 2025. This represents a meaningful validation from an established healthcare multi-strategy investor with deep oncology expertise, likely triggered by recent trial progress or upcoming catalysts in a therapeutic area with significant unmet need and commercial potential.

# Signal Note: Deerfield Initiates $207.6M Position in UTHR Deerfield's entry into UTHR (425,993 shares) signals conviction in United Therapeutics' pulmonary hypertension portfolio, likely driven by upcoming catalysts in Tyvaso DPI (inhaled treprostinil) label expansion or commercial uptake momentum, or advancement of next-gen therapies like selexipag follow-ons. The $207.6M position size reflects meaningful capital commitment from a specialized healthcare investor with strong drug development expertise, suggesting visibility into near-term value inflection. Watch for 2024-2025 regulatory decisions on indication expansions and quarterly revenue trends in core PH franchises.

**Signal Note: Deerfield Healthcare Multi-Strategy Initiates $205.6M VERA Position** Vera Therapeutics is advancing duokafide, a selective finerenone analog for IgA nephropathy (IgAN) currently in Phase 2b/3 development following positive Phase 2 data. Deerfield's $205.6M entry (4M shares) signals conviction in the competitive IgAN market, where finerenone (Kerendia) has established proof-of-concept but duokafide may offer improved selectivity; near-term catalyst is Phase 2b interim readout expected in 2H 2024. This represents meaningful dry powder deployment by an established healthcare investor, though regulatory and competitive risk remains material given crowded pipeline in this indication.

# Signal Note: Deerfield Management Initiates $180.7M Position in MIRM Deerfield's 70M share entry (substantial stake) suggests conviction in Mirum's pipeline, likely centered on maralixibat for progressive familial intrahepatic cholestasis (PFIC) and potential label expansions or late-stage data readouts. The timing and position size indicate confidence in either near-term regulatory catalysts, commercial execution, or M&A optionality in a rare disease space where Deerfield has demonstrated repeated success. Monitor upcoming clinical readouts and revenue trajectory against 2024-2025 guidance.

**SIGNAL: Deerfield initiates $171M position in CELC ahead of near-term TNBC readout.** The $1.7M share stake suggests conviction in gedatolisib's Phase 2 TNBC data (due 7/31/24), a notoriously difficult indication with limited PI3K/mTOR validation; positive efficacy could de-risk the larger HR+/HER2- breast cancer program and 2026 PDUFA. Watch for whether TNBC results support advancement to Phase 3 and inform gedatolisib's competitive positioning versus existing CDK4/6i + endocrine therapy standards.

**Signal Note: Deerfield Initiates $168M Position in Neurocrine** Deerfield's new 1.18M-share stake suggests conviction in Neurocrine's pipeline, likely driven by upcoming catalysts around GABA-A modulators for tardive dyskinesia (TAAR: Phase 3 readouts expected 2024-2025) or potential label expansions for established CNS franchises like elagolix. The $168M bet size indicates Deerfield sees asymmetric risk/reward in near-term clinical/commercial inflections for the company's neurology-focused platform.

**Signal Note: Deerfield Initiates $148M Position in NewAmsterdam Pharma** Deerfield's substantial entry suggests confidence in obicetrapib (OBICET), NewAmsterdam's CETP inhibitor currently in Phase 3 for cardiovascular risk reduction in statin-treated patients with elevated Lp(a)—a validated but underserved target following AstraZeneca's evacetrapib failure and Eli Lilly's recent positive Phase 2b data in the same space. Key catalysts include Phase 3 topline readout (expected 2025) and potential label expansion opportunities if efficacy holds, though CETP inhibitor class risk remains given prior clinical setbacks.

# Signal Note: Deerfield Initiates $139M Position in INSP Deerfield's $139M stake in Inspire Medical signals confidence in the company's sleep apnea franchise, particularly as the FDA recently expanded reimbursement coverage for its esteemed hypoglossal nerve stimulation (HGNS) device. The position size suggests conviction in near-term revenue acceleration driven by improved insurance access, which historically has been the primary constraint on INSP's commercial uptake in the obstructive sleep apnea market.

**Signal Note: Deerfield Initiates $129M Position in Legend Biotech** Deerfield's entry suggests conviction in LEGN's near-term commercial inflection, likely driven by JCARH125 (ciltacabtagene autoleucel) ramp in relapsed/refractory multiple myeloma following its December 2022 FDA approval and recent label expansions. The $129M stake signals confidence in execution against competitive CAR-T competitors (Janssen, Bluebird) and potential 2024-2025 revenue acceleration as manufacturing scale improves.

# Signal Note: Deerfield initiates $121.7M position in INDV Deerfield's entry into Indivior suggests conviction in the company's opioid-addiction pipeline, likely driven by buprenorphine formulation IP defensibility or upcoming label expansion catalysts (e.g., Sublocade dosing or new indication approvals). The $121.7M stake (~3.4M shares) represents a meaningful bet on Indivior's ability to maintain market exclusivity in medication-assisted treatment despite generic competition pressures on traditional buprenorphine/naloxone products.